Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Phio Pharmaceuticals ( (PHIO) ).
At the Annual Meeting, Phio Pharmaceuticals‘ stockholders elected six directors to serve until 2026, ratified Grant Thornton, LLP as the independent auditor for 2025, and approved an increase in shares for the 2020 Plan by 950,000. Additionally, they endorsed the executive compensation plan and decided on a three-year frequency for future advisory votes on executive compensation, reflecting a strategic alignment with stockholder preferences.
The most recent analyst rating on (PHIO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Phio Pharmaceuticals stock, see the PHIO Stock Forecast page.
Spark’s Take on PHIO Stock
According to Spark, TipRanks’ AI Analyst, PHIO is a Neutral.
Phio Pharmaceuticals is struggling financially, with no revenue and consistent losses, significantly impacting its stock score. The technical indicators show mixed signals, with some short-term momentum but bearish long-term trends. The valuation is speculative due to negative earnings. The recent board appointment is a positive corporate event but has limited impact on overall financial health.
To see Spark’s full report on PHIO stock, click here.
More about Phio Pharmaceuticals
Average Trading Volume: 975,082
Technical Sentiment Signal: Sell
Current Market Cap: $12.48M
See more data about PHIO stock on TipRanks’ Stock Analysis page.